A Phase 1 Study of BMS-986460 in People With Metastatic Castration-Resistant Prostate Cancer


Full Title

A Phase 1, Open-label Study of BMS-986460 in Participants with Metastatic Castration-resistant Prostate Cancer


Prostate cancers initially need the male hormone testosterone for growth. Hormone therapies that lower the level of testosterone are among the best treatments for prostate cancers that have metastasized (spread). The benefits of hormone treatments do not last, however. Over time, many prostate cancers keep growing even with hormonal therapies. These are called metastatic castration-resistant prostate cancers (mCRPC).

Researchers in this study want to find the best dose of BMS-986460 to use in people with mCRPC. BMS-986460 targets and gets rid of a protein in prostate cancer cells called the androgen receptor (AR). This protein boosts prostate cancer growth by allowing cancer cells to resist anti-cancer treatments. Blocking the effects of the AR protein can slow or stop prostate cancer growth. BMS-986460 is taken orally (by mouth).

Who Can Join

To join this study, there are a few conditions. You must:

  • Have mCRPC that keeps growing even after treatment.
  • Have stopped taking abiraterone acetate, rucaparib, or olaparib at least 2 weeks before taking BMS-986460 and other therapies at least 4 weeks before.
  • Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
  • Be age 18 or older.


For more information and to see if you can join this study, please call Dr. Dana Rathkopf’s office at 646-422-4379.




Phase I (phase 1)

Disease Status

Relapsed or Refractory



ClinicalTrials.gov ID